S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
S&P 500   3,971.27 (-0.16%)
DOW   32,394.25 (-0.12%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
NASDAQ:AKER

Akers Biosciences - AKER Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$1.54
▼
$1.61
50-Day Range
$2.47
▼
$4.59
52-Week Range
$1.65
▼
$6.97
Volume
660,943 shs
Average Volume
769,876 shs
Market Capitalization
$25.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

AKER stock logo

About Akers Biosciences (NASDAQ:AKER) Stock

Akers Biosciences, Inc. focuses on the development of a vaccine candidate against SARS-CoV-2, a coronavirus causing a pandemic. It has a collaboration agreement with Premas Biotech PVT Ltd. The company was incorporated in 1989 and is headquartered in New York, New York.

Receive AKER Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akers Biosciences and its competitors with MarketBeat's FREE daily newsletter.

AKER Stock News Headlines

March 15, 2023 | marketwatch.com
Rapid Tests Market Application, Product, Sales and Forecast 2023-2028
March 12, 2023 | marketwatch.com
Global Rapid Tests Market to by In-depth Analysis of Revenue Forecast and Competitive Landscape 2030 By VMReports
March 28, 2023 | Investor Place Media (Ad)
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
March 1, 2023 | marketwatch.com
2023-2029 Cholesterol Testing Market Size and Growth Analysis | Research Report by Absolute Reports
February 28, 2023 | msn.com
Stylist Zerina Akers’ Best Career Advice for Young Creatives: ‘Just Be Nice’
February 23, 2023 | marketwatch.com
Global Breath Analyzer Devices Market Size Opportunities, Regional Overview, Top Leaders, Revenue and Forecast to 2030 By VMReports
February 21, 2023 | marketwatch.com
Global Non- Invasive Biosensors Market 2023 Industry Size, Share, Trends, Opportunities, Growth Analysis and Forecast to 2030 By VMReports
February 20, 2023 | marketwatch.com
Rapid Tests Market Size, Share and Forecast 2028 with Top Countries Data
March 28, 2023 | Weiss Ratings (Ad)
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
February 9, 2023 | marketwatch.com
Alco-Sensor FST Market Research 2023 : Growth, Trends, Outlook and Future Scope Analysis 2028
January 25, 2023 | marketwatch.com
Oral Anticoagulant Market : Reliable Business Data Analysis and Forecast by 2028 with Top Countries Data
January 23, 2023 | marketwatch.com
Cholesterol Testing Market to Receive Overwhelming Hike in Revenues by 2030 With key Players Abbott Diagnostics, Inc., AccuTech, LLC
January 9, 2023 | msn.com
Cam Akers Finishes Season On Three-Game 100-Yard Streak
January 8, 2023 | msn.com
Family of Akers Way 'hit and run' victim reveal plans for road safety campaign
January 7, 2023 | msn.com
Cam Akers Could Continue Rushing Hot Streak In Week 18
January 4, 2023 | msn.com
'Noles in the Pros: Week 17, Akers stays hot as he battles Samuel Jr.
January 2, 2023 | msn.com
Watch highlights from Cam Akers' huge game vs. Chargers
January 2, 2023 | msn.com
Cam Akers Starts a Rams Streak That Hasn't Been Hit Since 2018
January 2, 2023 | msn.com
Sean McVay shares what's impressed him about Cam Akers during recent stretch
January 2, 2023 | msn.com
Cam Akers Offers Hope For Rams Running Game in Blowout Chargers Loss
January 2, 2023 | msn.com
Rams RB Cam Akers continues late-season surge with another 100-yard performance
January 2, 2023 | msn.com
Cam Akers is making Rams' decision at RB much easier in 2023
December 31, 2022 | forbes.com
Los Angeles Rams’ Cam Akers Is Finding Plenty Of Green After Escaping Sean McVay’s Doghouse
December 30, 2022 | msn.com
Cam Akers An RB2 With RB1 Upside
December 30, 2022 | theramswire.usatoday.com
Cam Akers player props odds, tips and betting trends for Week 17 | Rams vs. Chargers
December 29, 2022 | msn.com
Sean McVay Sees Cam Akers In Rams’ Long-Term Plans
December 29, 2022 | msn.com
Cam Akers May Stick Around In LA
See More Headlines
Receive AKER Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akers Biosciences and its competitors with MarketBeat's FREE daily newsletter.

AKER Company Calendar

Last Earnings
11/15/2018
Today
3/28/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Diagnostic Substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AKER
CUSIP
N/A
CIK
1321834
Web
www.akersbio.com
Phone
856 848 8698
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-3,890,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-87.42%
Return on Assets
-73.31%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.22
Quick Ratio
9.22

Sales & Book Value

Annual Sales
$1.58 million
Price / Sales
16.44
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.38 per share
Price / Book
0.29

Miscellaneous

Outstanding Shares
16,653,000
Free Float
N/A
Market Cap
$25.98 million
Optionable
Not Optionable
Beta
0.30

Key Executives

  • Mr. Christopher C. Schreiber (Age 56)
    CEO, Pres & Director
    Comp: $507.62k
  • Mr. Ian Rhodes (Age 48)
    Interim Chief Financial Officer
  • Mr. Gary M. Rauch (Age 65)
    VP of Fin. & Treasurer

Key Competitors

View All Competitors













AKER Stock - Frequently Asked Questions

How were Akers Biosciences' earnings last quarter?

Akers Biosciences, Inc. (NASDAQ:AKER) released its quarterly earnings results on Thursday, November, 15th. The medical instruments supplier reported ($0.26) earnings per share for the quarter. The medical instruments supplier had revenue of $0.56 million for the quarter.

What is Thomas A. Nicolette's approval rating as Akers Biosciences' CEO?

3 employees have rated Akers Biosciences Chief Executive Officer Thomas A. Nicolette on Glassdoor.com. Thomas A. Nicolette has an approval rating of 64% among the company's employees.

What other stocks do shareholders of Akers Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akers Biosciences investors own include ImmunoGen (IMGN), Sorrento Therapeutics (SRNE), AVEO Pharmaceuticals (AVEO), Advanced Micro Devices (AMD), Aytu BioPharma (AYTU), Biopharmx (BPMX), Neovasc (NVCN), Micron Technology (MU), Vaxart (VXRT) and Anavex Life Sciences (AVXL).

What is Akers Biosciences' stock symbol?

Akers Biosciences trades on the NASDAQ under the ticker symbol "AKER."

What is Akers Biosciences' stock price today?

One share of AKER stock can currently be purchased for approximately $1.56.

How much money does Akers Biosciences make?

Akers Biosciences (NASDAQ:AKER) has a market capitalization of $25.98 million and generates $1.58 million in revenue each year.

How can I contact Akers Biosciences?

Akers Biosciences' mailing address is 201 GROVE RD, THOROFARE NJ, 08086. The official website for the company is www.akersbio.com. The medical instruments supplier can be reached via phone at 856 848 8698 or via email at investors@akersbio.com.

This page (NASDAQ:AKER) was last updated on 3/28/2023 by MarketBeat.com Staff